1. The investment comes from Tokyo-based Terumo Corp., Vascutek’s parent company and a leading medical device manufacturer.
2. Vascutek will use the funds to create and stock two cleanrooms, which are controlled environments for producing medical implants. It will also develop a sterilization suite.
3. “This is an extremely exciting time for the company as we look to secure further growth in the surgical grafts market,” Vascutek President and CEO Paul Holbrook told The Gazette.
4. The upgrade is set to begin in April and expected to be complete in 2021.
5. Vascutek manufactures a variety of implants but focuses on aortic disease treatments.
More articles on supply chain:
McKesson reports $53.6B in Q3 revenue — 7 insights
Global surgical robotics market to experience double-digit growth — 8 insights
Cary Skin Center turns 20
